This assay for oxalate in serum or plasma, by a radioenzymatic isotope dilution technique, is sensitive, specific, and accurate. The oxalate in 5 mL of serum or plasma ultrafiltrate is precipitated with Ca2, dissolved in acid, extracted with ether, and the extract evaporated under nitrogen and redissolved in citrate buffer. The oxalate in this solution is decarboxylated with oxalate decarboxylase (EC 4.1.1.2) in the presence of [14C]oxalate to evolve labeled and unlabeled CO2. An equation derived by Newsholme and Taylor [Biochim. Biophys. Acta 158, 11(1968)] described quantitatively the simultaneous effects of variation of non-radioactive substrate on isotope dilution and enzyme velocity, resulting in a linear standard curve. We found the Km for this enzyme to be 31.0 zmoi/L, with an assay sensitivity of 0.5 tg and a linear assay range to 10 pg. The sensitivity of this result was consistent with the value of 0.1 Km predicted from the equations of Newsholme and Taylor. The K1values for phosphate and sulfate, two commonly occurring inhibitors of the enzyme that affect assay sensitivity by the relationship Km (1 + l/K), were 12 and 7 mmol/L, respectively. Analytical recovery of 0.5-2.0 mg of unlabeled oxalate added to serum per liter was 95.4 ± 5.7% (SE). Inter-and intra-assay precision was excellent (coefficients of variation of 6.0 and 7.7%, respectively). Dilution of serum or plasma citrate buffer extracts over an eightfold range yielded plots parallel to the standard curve, indicating the absence of enzyme inhibitors or activators in the citrate buffer extracts. The mean oxalate concentrations in serum and plasmameasured in nine and six male volunteers, respectively-were 0.83 ± 0.24 mg/L (SD) and 0.96 ± 0.24 mg/L (SD). 
was 95.4 ± 5.7% (SE). Inter-and intra-assay precision was excellent (coefficients of variation of 6.0 and 7.7%, respectively). Dilution of serum or plasma citrate buffer extracts over an eightfold range yielded plots parallel to the standard curve, indicating the absence of enzyme inhibitors or activators in the citrate buffer extracts. The mean oxalate concentrations in serum and plasmameasured in nine and six male volunteers, respectively-were 0.83 ± 0.24 mg/L (SD) and 0.96 ± 0.24 mg/L (SD). 
normal values (men)
Because oxalic acjd in the presence of oxalate decarboxylase (oxalate carboxy-lyase, EC 4.1.1.2) decomposes to formic acid and CO2 (1), previously reported enzymatic assays for oxalate have depended on measuring the CO2 evolved or the formic acid released. We described elsewhere a radioenzymatic isotope-dilution assay for urinary oxalate (2) involving oxalate decarboxylase, which is relatively simple, accurate, specific, and sensitive and alleviates problems of earlier urine enzymatic methods (3-fl) . Here we describe a modification of this assay, which enables measurement of oxalate in either serum or plasma. The progress of the reaction is followed by using [14C]oxalic acid and measuring the 14C evolved. Addition of unlabeled substrate under these conditions results in two opposing phenomena. First, the addition of unlabeled sub- strate to labeled substrate will decrease the specific activity of the substrate, and incorporation of label from substrate into product will be decreased according to sub-stoichiometric isotope dilution (7) . Second, in opposition to the first process, at substrate concentrations below about 10 Km, production of "C will be increased because of the greater velocity of the enzyme reaction associated with the increased substrate concentration. The magnitude of these effects is quantitatively predictable from the sub-stoichiometric isotope-dilution principle (7) and kinetics. Combining the isotope-dilution effects and the enzyme-activity effects, Newsholme and Taylor (9) derived an equation for a standard curve:
where C0 and C8are the total amount of #{176}4C from [14C]oxalate incorporated into "C-labeled product with labeled substrate only (C0) or with unlabeled substrate (C8) also present. S0 and S represent the concentration of labeled and unlabeled substrate, respectively, and Km is the Michaelis constant.
A plot ofCO/CS vsS will be linear, with a slope of 1/(Km + S0). CO/CS will be unity when S is zero. When 5,>> Km, the slope of the line will be 1/5,,. This plot is preferable to the linear plot for the standard curve described in our previous urinary assay (2) because the Newsholme-Taylor equation, when rearranged, can yield a value for Km that can be used to check uniformity with each assay:
Material and Methods
Isotope Preparation (2) Dilute [14C]oxalic acid (sp. acty., 40-60 Ci/mol; Amersham Corp., Arlington Heights, IL 60005) in water to 100 mCi/Land store in 25-L aliquots at -90 #{176}C. Dilute each aliquot to about 40 000 cpm/0.1 mL with citrate buffer (0.1 mol/L, pH 3.0). Make this dilution with each assay. Under the assay conditions some 14C evolves from this solution even when no enzyme is present, ranging from slightly above background to -400 cpm. Therefore, include blanks with every assay. Refrigerate all solutions when not in use.
Enzyme Preparation
An enzyme unit is defined by each supplier (Worthington To determine what dilution of enzyme to use, set up a series of four "zero" tubes and fourtubescontaining 4 zg of oxalate standard as described below under Enzyme Assay. Thaw 0.1 mL of enzyme (0.2 units) and dilute with citrate buffer (0.1 mol/L, pH3.0) to 10 milliunits/0.1 mL, to7.5 milliunits/0.1 mL, to 5 milliunits/0.1 mL, and to 2.5 milliunits/0.1 mL. Add 0.1 mL of each dilution to the "zero" and 4-tg tubes and incubate as described under Enzyme Assay. Use the dilution of enzyme that evolves between 10 000 and 1 000 counts from the "zero" tube and 1000 to 1200 counts from the 4-pg tube in 8 mm for the assay.
Serum or Plasma Preparation
Add ['4C]oxalic acic(20oOocpm) asan internal standard to15 mL of fresh serum or plasma and measure the radioactivity in a 0.1-mL aliquot. Ultrafilter the serum orlasma, using Centriflo membrane cones (CF5OA or CF25; Amicon, Lexington, MA 02173) in a refrigerated centrifuge at 750 X g for 60 mm. Neutralize a 5.0-mL aliquot of the clear ultrafiltrate to pH 7.0 ± 0.1 with 0.1 mol/L HC1. Add 0.5 mL of 20 g/L CaC12.2H20, followed by 95% ethanol to make the final concentration of alcohol 750 mL/L (10). Mix gently and allow this solution to stand for at least 3 h (preferably overnight) at room temperature. Centrifuge the sample at4 #{176}C at 800 X g for 15 mm, discard the supernatant fluid, and drain the tube. Dissolve the precipitate in 1 mL of 0.3 mol/L hydrochloric acid and extract with 10 mL of aiesthesia-grade diethyl ether, saturated with dilute (0.3 mol/L) HC1. Transfer the ether layer to a scintillation vial and evaporate it under nitrogen at room temperature. Repeat the ether extraction and evaporation four more times, placing the extracts in the same vial. At this point the oxalate in the sample is stable when stored at -20 #{176}C. Add 1 mL of sodium citrate buffer (0.1 mol/L, p1-I 3.0) to the residue and agitate vigorously. Measure the oxalate in this citrate buffer extract by the enzyme assay and, to correct for procedural losses of oxalate, determine the radioactivity of the internal standard in a 0.1-mL aliquot. Before placing it in the well, saturate each filter-paper strip with 25 iiL of CO2 absorber (OxysorbCO2; New England Nuclear, Boston, MA 02118) and allow to air dry for 10 to 20 mm. Position the well about 2.5 cm below the bottom of the cap (2) . Swirl the tubes ahd incubate them at 31 #{176}C for 8 mm in a shaker (120 cycles/mm). Using a 1-mL syringe fitted with a 20-gauge 25-40 mm needle, inject 0.2 mL of 100 g/L tnchioroacetic acid through the cap. Run standards (0.25-4 sg) and samples in triplicate, along with "no enzyme" controls containing 0.1 mL of buffer instead of enzyme and "zero oxalate" tubes containing 0.2 mL of buffer instead of unlabeled oxalate.
Shake the tubes for 60 mm at 31 #{176}C to trap evolved 14c.
Remove the strip and measure its radioactivity in a toluene scintillation cocktail containing, per liter, 5 g of 2,5-diphenyloxazole, 0.1 g of 1,4-bis[2(5-phenyloxazolyl)]benzine, and 34.5 mL of NCS solubilizer (Amersham). Correct for procedural losses by determining the radioactivity of the ["CI oxalate internal standard in 0.1 mL of the citrate buffer extract of serum or plasma ultrafiltrate.
Using a Model 3330 Tri-Carb Liquid Scintillation Spectrometer (Packard-Instrument Co., Downers Grove, IL 60515), we calculated a 14C-counting efficiency of 84% by determining the cpm of the L14Cltoluene standard (New England Nuclear, lot 697-65) with known dpm in the scintillation fluid. A lesser '4C-counting efficiency will proportionately reduce the absolute sensitivity of the assay.
Assay Calculations
Obtain values for the y-axis by making the following catculations: If A = evolved '4C cpm from oxalate standards or unknown extract tubes (containing [t4Cloxalate, standard oxalate, or serum or plasma extract, EDTA, and enzyme), and B = evolved 14Ccpm from "no enzyme" control tubes (containing [14C]oxalate, EDTA, and buffer), and Z = evolved "C from "zero oxalate" control tubes (containing [14C]oxalate, EDTA, buffer, and enzyme), then A -B = C5(corrected cpm for standards or unknown) and Z -B = C0 (corrected cpm for zero unlabeled oxalate). Plot CO/CS on the y-axis.
Plot the micrograms of unlabeled oxalate on the x-axis. Calculate the oxalate concentrations of the unknown extracts in micrograms from the standard curve (Figure 1) , which satisfies the equation for a straight line: y = mx + b, where y = C,,/C, x = micrograms of unlabeled oxalate in assay tube, m = slope of the standard curve, and b = y-intercept 1.0. Finally, calculate milligrams of oxalate per liter of serum or plasma = x X R X 1000, where x = g of oxalate in assay tube; and R (recovery) = (cpm of 0.1 mL of serum or plasma X 50)/(cpm of 0.1 mL of ultrafiltrate citrate extract X 10). The 50 corrects to total volume of serum or plasma and the 10 corrects to total volume of citrate extract.
Results
Oxalate was measured after precipitation as calcium oxalate from serum or plasma ultrafiltrates and extraction with ether and citrate buffer. When protein was removed by precipitation with trichloroacetic acid or perchlonic acid, we had poor ana- The concentration of unlabeled substrate was increased in the presence of a constant amount of radioactive substrate and the 14Cevolved was measured; calculating the Km from the latter data, used to prepare a standard curve (Figure 1 ) according to the above equations 1 and 2 of Newsholme and Taylor (9), we obtained a value of 31.0 zmol/L. We made the same studies on enzyme preparations from three other commercial sources, to evaluate their uniformity. The Km for the Aldrich enzyme preparation was 35.5 mol/L, for the Sigma preparation, 80.0 mol/L, and for the U.S. Biochemical preparation, 24.0 tmol/L.
To assess the effects on the sensitivity of the assay of inhibitors of oxalate decarboxylase known to be present in urine, serum, plasma, and other biological materials, we determined the K1 (13) for phosphate and for sulfate, which we found to be 12 and 7 mmol/L, respectively.
We measured the concentration of oxalate in fresh serum from nine apparently healthy male volunteers who had fasted overnight ( Table 2 ). The thean was 0.83 ± 0.24 mg/L (SD). The concentration of oxalate in the corresponding fresh plasma from six of the volunteers was also measured. The mean oxalate concentration in plasma was 0.96 ± 0.34 mg/L (SD) ( Table 2 ). There was no significant difference between these means, or between the paired measurements of the six individual serum and plasma samples. 1) . A similar recovery was obtained for plasma (data not shown). The coefficientof variation (CV) for triplicate determinations of triplicate precipitations of pooled serum that had been stored frozen was 6.0%. We observed a 7.7%CV for evaporated ether extracts of serum stored for several weeks at -20 #{176}C.
The oxalate concentrations after diluting the serum citrate extract over an eightfold range are shown in Figure 2 . The proportionality between the oxalate concentrations in diluted serum extracts and the oxalate values from the standaid curve indicates the absence of either activators or inhibitors of the enzyme in the serum extract (11) . This parallelism also indicates that the substance in the extract has the same effect on 'C production as does oxalate, strongly suggesting that the
Discussion
The sensitivity of the various serum and plasma enzymatic methods varies from C).05mg/L by the method of Knowles and Hodgkinson (14) to 8 mg/L by the method of Crawhall and Watts (15) . The sensitivity of the double-enzyme method (16) for serum is not reported, but the absolute sensitivity of the method for urine is reported to be 2.0 tg (6). We obtained an absolute sensitivity of 0.5 .tg.
The reported interaSsay CV of other methods ranges from 5% in the continuous-flow method (14) to 11.5% in the double-enzyme method (16) . In the other assays for serum or plasma oxalate (14-16) there were no reports of intra-assay Chambers and Russell (17) report that oxalate binding to serum proteins is significant at acid pH. We recovered oxalate quantitatively after ultrafiltering serum and plasma without first adjusting the pH to 10.6, as described by Hatch et al. (16) . Our best recoveries were obtained with Ca2 precipitation of the oxalate in serum or plasma ultrafiltrates. By our method, the percentage recovery of unlabeled oxalate added to serum (95.4 ± 5.7% SE) was essentially the same as with the double-enzyme method (16) (102.9 ± 5.3% SE) and the continuous-flow method (14) (110 ± 1.8% SE).
All the enzymatic assays share the advantage of the specificity of the enzyme. Two methods measure CO2 by relatively inaccurate methods: Warburg manometry (15) and titration (14) . The double-enzyme method measures formate by the absorbance changes resulting from reaction with formate dehydrogenase (EC 1.2.1.2) and NAD, and thus must be corrected for endogenous substances that cause erroneous absorbances. Each of these oxalate assays depends upon complete quantitative conversion of substrate to product. Our assay, which is based on the enzyme-isotope-dilution principles described by Newsholme and Taylor (9), depends upon the progress of conversion of substrate to product and thus is subject to interference by substances that affect the rate of the enzyme reaction. We avoided interfering substances, as demonstrated by the parallelism in Figure 2 , by purifying the oxalate by precipitation from ultrafiltrates and extracting it before measurement. Similar results were obtained by the double-enzyme method of Costello et al. (16) .
As pointed out by Newsholme and Taylor, the absolute sensitivity of this assay depends upon the Michaelis-Menten constant (Km) of the oxalate decarboxylase. Better to define the utility and sensitivity of the assay, we determined the Km by two methods, as well as the effects upon Km of two common radicals, phosphate and sulfate, which are present in appreciable quantities in most biological materials. The effect of an inhibitor upon Km can be quantitatively estimated from the relation Km (1 + I/I(i) (11) . The only reported Km (1) for oxalate decarboxylase, 2.05 X i0 mol/L, was determined at 37 #{176}C in the presence of phosphate (50 mmol/L), which is a competitive inhibitor of the enzyme. The hitherto unreported K1 (12 mmol/L) for phosphate does not account for the 100-fold discrepancy between the Km value of 31 imol/L we observed and the reported value. The effect of phosphate on the Km in this case could account only for a fivefold change of Km.
The sensitivity of our method (0.5 pig) was close to the theoretical sensitivity of 0.1 Km (9) if the true Km, as we observed, is about 3 X 10 mol/L. The K1 for sulfate, 7 mmolfL, is also reported here for the first time.
The mean oxalate concentration in theserum of healthy men has been reported as 1.17 ± 0.20 mg/L (SD) by the continuous-flow method (14) and 1.30 ± 0.42 mg/L (SD) by the double-enzyme method (16). Our mean was 0.83 ± 0.24 mg/L (SD) ( Table 2 ). Our lower value might have resulted because the nine apparently healthy men were fasting. Conversely, the higher value of Knowles and Hodgkinson (14) might have resulted from the gentle boiling of the ultrafiltrate, which may convert other substances to oxalate. Furthermore, the samples were stored at 4 #{176}C until analysis. We (2) and others (3) have shown that oxalate increases upon storage.
In the doubleenzyme procedure the calcium precipitates are dried at 105 #{176}C for 30 mm, then dissolvedin citrate buffer at 75 #{176}C for 15 mm, which may produce oxalate from other constituents such as calcium ascorbate. Very recently, a radionuclide-dilution assay (18) 
